Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:4592
Structure:
Synonyms:
"insolution™ olomoucine"
101622-51-9
2-(2-Hydroxyethylamino)-6-benzylamino-9-isopropylpurine
2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine
2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine
2-[[6-(benzylamino)-9-methylpurin-2-yl]amino]ethanol
2-[[9-methyl-6-(phenylmethylamino)purin-2-yl]amino]ethanol
2-[[9-Methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-ethanol
2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol
4erk
6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine
6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine
6-benzylamino-2-[2-hydroxyethylamino]-9-methylpurine
AC1L1IID
AC1Q4XZU
AIDS-007464
AIDS007464
AKOS005145988
AR-1D7506
BCBcMAP01_000205
Bio1_000336
Bio1_000825
Bio1_001314
Bio2_000335
Bio2_000815
BiomolKI2_000052
BiomolKI_000046
BMK1-E10
BRD-K82731415-001-03-9
BRD-K82731415-001-04-7
BSPBio_000990
C090046
CBiol_002050
CCG-100650
CHEBI:44661
CHEMBL280074
CPD-5442
DB02116
Ethanol, 2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-
EU-0100883
HMS1362B11
HMS1792B11
HMS1990B11
HMS3262B08
IDI1_002090
IN1179
IN1182
InSolution&trade
InSolution™ Olomoucine
KBio2_000330
KBio2_002898
KBio2_005466
KBio3_000659
KBio3_000660
KBioGR_000330
KBioSS_000330
Kinome_2870
Lopac-O-0886
Lopac0_000883
MolPort-003-849-700
NCGC00015763-01
NCGC00015763-02
NCGC00015763-03
NCGC00015763-04
NCGC00015763-05
NCGC00015763-06
NCGC00015763-07
NCGC00015763-08
NCGC00015763-09
NCGC00025096-01
NCGC00025096-02
NCGC00025096-03
NCGC00025096-04
NCGC00025096-05
NCGC00025096-06
NCGC00025096-07
NCI60_022916
NSC666096
O 0886
O0886_SIGMA
OLO
Olomoucine
SMP1_000281
ST50298830
ST5298830
Tocris-1284
UPCMLD-DP136
UPCMLD-DP136:001
UPCMLD-DP136:002
ZINC01641925

Target

show target details
Uniprot ID:Q6GXA5_MOUSE
Synonyms:
Matrix metalloproteinase 2
EC-Numbers:-
Organism:Mouse
Mus musculus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

18385789
The Cdk5 inhibitor olomoucine promotes corneal debridement wound closure in vivo.. Brajendra K Tripathi; Mary A Stepp; Chun Y Gao; Peggy S Zelenka (2008) Molecular vision display abstract
PURPOSE: To investigate the effect of the Cdk5 inhibitor olomoucine on corneal debridement wound healing in vivo. METHODS: Corneal debridement wounds of 1.5 mm were made on the ocular surface of CD-1 mice. A 20 microl drop of 15 microM olomoucine in 1% DMSO was applied to the wound area immediately after wounding and again after 6 h. Control mice received identical applications of 1% DMSO. Mice were euthanized after 18 h, two weeks, and three weeks for evaluation of wound healing and restratification. Corneas were stained with Richardson's dye, photographed, and processed for histology and immunofluorescence as whole mounts or paraffin sections. The remaining wound area at 18 h was measured by image analysis. Scratch wounded cultures of human corneal-limbal epithelial cells (HCLE) were used to examine the effect of olomoucine on matrix metalloproteinase (MMP) expression in vitro. MMP-2 and MMP-9 were detected by immunofluorescence and immunoblotting. RESULTS: Olomoucine treatment significantly enhanced corneal wound closure without increasing inflammation or infiltration of polymorphonuclear leukocytes 18 h after wounding (p